Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnWeb3SquareMore
Trade
Spot
Buy and sell crypto with ease
Margin
Amplify your capital and maximize fund efficiency
Onchain
Going Onchain, without going Onchain!
Convert & block trade
Convert crypto with one click and zero fees
Explore
Launchhub
Gain the edge early and start winning
Copy
Copy elite trader with one click
Bots
Simple, fast, and reliable AI trading bot
Trade
USDT-M Futures
Futures settled in USDT
USDC-M Futures
Futures settled in USDC
Coin-M Futures
Futures settled in cryptocurrencies
Explore
Futures guide
A beginner-to-advanced journey in futures trading
Futures promotions
Generous rewards await
Overview
A variety of products to grow your assets
Simple Earn
Deposit and withdraw anytime to earn flexible returns with zero risk
On-chain Earn
Earn profits daily without risking principal
Structured Earn
Robust financial innovation to navigate market swings
VIP and Wealth Management
Premium services for smart wealth management
Loans
Flexible borrowing with high fund security
Bitcoin News Update: Propanc’s Cryptocurrency-Driven Cancer Initiative Encounters Doubt from Investors, Stock Falls by 10.5%

Bitcoin News Update: Propanc’s Cryptocurrency-Driven Cancer Initiative Encounters Doubt from Investors, Stock Falls by 10.5%

Bitget-RWA2025/11/11 00:06
By:Bitget-RWA

- Australia-based Propanc Biopharma secured up to $100M from Hexstone Capital to build a crypto treasury and advance its cancer therapy PRP, targeting first-in-human trials by 2026. - The funding strategy reflects a growing trend in biotech to leverage crypto assets for non-dilutive capital, with Hexstone’s portfolio including Bitcoin , Ether , and Solana . - CEO James Nathanielsz called the move "transformative," aiming to diversify Propanc’s assets while tying capital to clinical milestones, though share

Headquartered in Australia,

has obtained a funding commitment of up to $100 million from Hexstone Capital, a family office specializing in cryptocurrency, to build a digital asset treasury and further its cancer treatment research . The agreement starts with an initial $1 million investment via convertible preferred shares, followed by the possibility of an additional $99 million over the coming year . The capital will be used to establish a crypto treasury and speed up the development of its flagship therapy, PRP, which is slated to begin its first human trials in the latter half of 2026 . CEO James Nathanielsz called this a "transformative period" for the company, highlighting the opportunity to bolster Propanc’s financial position and broaden its asset portfolio .

This financing approach mirrors a rising trend among biotech companies turning to crypto treasuries as traditional capital markets become more challenging. Firms such as Sonnet BioTherapeutics and Sharps Technology have also embraced digital asset strategies to attract investors and diversify their funding streams

. Industry experts note that this movement has since 2023, as biotech companies look for non-dilutive funding in the $2.5 trillion crypto sector . However, Propanc’s strategy has received a mixed response from the market.
Bitcoin News Update: Propanc’s Cryptocurrency-Driven Cancer Initiative Encounters Doubt from Investors, Stock Falls by 10.5% image 0
Shares of (PPCB) dropped by 10.5% on Nasdaq after the news, adding to a 46.7% decrease over the previous month . This decline highlights investor caution regarding the integration of crypto assets in established industries, especially given recent fluctuations in and values .

Hexstone Capital, which has supported other crypto treasury projects, has not specified which digital assets Propanc intends to purchase. Still, its holdings include Bitcoin (BTC), Ether (ETH),

(SOL), and Injective (INJ), suggesting a focus on high-growth cryptocurrencies . Propanc’s CEO pointed out that the company’s proenzyme therapy is designed to treat both solid tumors and chronic illnesses, utilizing a distinct mechanism of action . The company’s funding model aims to address common biotech financing hurdles by linking capital releases to clinical progress, ensuring that resources are directed toward research and development rather than speculation .

The broader landscape for crypto treasury firms has encountered difficulties, with companies like Strategy and Metaplanet seeing notable drops in market capitalization

. Despite these obstacles, Propanc’s phased funding approach—allocating capital incrementally to clinical trials and treasury growth—aims to balance innovation with financial discipline . Analysts observe that while crypto-based fundraising can be 20-30% faster than conventional methods , it also brings regulatory and market volatility risks. The SEC’s increased attention to crypto reporting adds complexity, requiring clear and accurate disclosures to protect investors .

Propanc’s combined focus on cancer research and digital assets places it at the crossroads of two rapidly expanding industries. Preclinical studies of PRP have demonstrated a 70% reduction in tumor size in animal tests

, offering new hope for patients with advanced cancers. As the company moves toward human trials in 2026, investors will be monitoring both clinical progress and market conditions to assess the sustainability of its dual-pronged strategy .

0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

PoolX: Earn new token airdrops
Lock your assets and earn 10%+ APR
Lock now!